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Insulin stimulated the activity of a high-affinity GTPase activity in human platelet membranes ome 62% 
over that of the basal activity. Half-maximal stimulation (K,) was achieved with 3.1 nM insulin. The K,,, 
for GTP of the insulin-stimulated GTPase was 0.6 ,uM GTP. Treatment of isolated platelet membranes with 
cholera toxin, but not pertussis toxin, blocked insulin’s ability to stimulate GTPase activity. Cholera toxin 
acted as a more potent inhibitor of the insulin-stimulated GTPase activity than that of the GTPase activity 
of the stimulatory guanine nucleotide regulatory protein, G,, as monitored by stimulation using prosta- 
glandin El (PGE,). Mixed ligand experiments howed that insulin stimulated GTPase activity in an additive 
fashion to GTPase activity stimulated by PGEr, due to G,; by adrenaline (+ propranolol), due to the inhibi- 
tory guanine nucleotide regulatory protein, Gi and by vasopressin, which stimulates the putative ‘G,‘, a 
G-protein suggested to control the stimulation of inositol phospholipid metabolism. Insulin thus appears 
to stimulate a novel high-affinity GTPase activity in human platelet membranes. This may reflect the func- 
tioning of the putative Gins, a guanine nucleotide regulatory protein which has been suggested to mediate 
certain of insulin’s actions on target tissues. 
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1, INTRODUCTION 
The plasma membrane of the platelet expresses 
a spectrum of receptors [l] including ones which 
are capable of binding insulin with high affinity 
[2,3]. It is now evident [4-81 that many cell surface 
receptors exert their actions by interacting with 
specific guanine nucleotide regulatory proteins (G- 
proteins). These G-proteins, upon interaction with 
an appropriate occupied receptor, bind GTP in 
order to attain an activated state capable of in- 
teracting with, and thereby modulating the activity 
of, a defined effector system. The ensuing deac- 
tivation cycle involves the concomitant hydrolysis 
of GTP. The activity of various G-proteins can 
thus be followed by the expression of high-affinity 
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receptor-stimulated GTPase activity. 
Purification [7-91 and molecular cloning techni- 
ques [lo, 1 l] have demonstrated that there are a 
large family of G-proteins associated with cells, 
many of whose functions have yet to be elucidated. 
They have a GTP-binding (a) subunit and are 
often found complexed with /3 and y components. 
Platelets are known to express the stimulatory G- 
protein G,, whose activity can be stimulated by 
both prostaglandin Ei and by isoprenaline [12,131; 
the inhibitory G-protein Gi, whose activity can be 
stimulated by both cuz-adrenergic agonists [I] and 
by thrombin [14,15], and a GTPase activity which 
is activated by ligands which stimulate inositol 
phospholipid metabolism [ 14-161. This latter G- 
protein, which has been termed ‘Gp’ [17], can be 
stimulated by vasopressin [ 14,161, platelet- 
activating factor [ 16,181 and thrombin [ 14,151. 
Other GTP-binding proteins are evident in 
platelets and a novel species with a 25 kDa a- 
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subunit has recently been purified although no 
function has yet been ascribed to it [19]. 
We [5,20-221 have suggested that insulin might 
exert certain specific effects on target tissues by in- 
teracting with the G-protein system in plasma 
membranes. This was based upon investigations of 
the ability of insulin both to inhibit adenylate 
cyclase [22] and to activate a high-affinity 
peripheral plasma membrane cyclic AMP 
phosphodiesterase [23]. Our studies indicated that 
insulin might interact with a novel G-protein, call- 
ed Gins, an d which could be activated by cholera 
toxin [22-241. Recently it has been suggested 
[25,26] that insulin might produce intracellular 
second messengers through the stimulation of a 
unique phosphatidylinositol-specific phospholip- 
ase C. By analogy with hormones which stimulate 
phosphatidylinositol 4,5bisphosphate breakdown 
[ 14- 181, a novel G-protein may serve to link the in- 
sulin receptor with the specific phospholipase C in- 
volved. 
Here, using human platelets, we demonstrate 
that insulin stimulates a novel GTPase activity 
whose functioning is inhibited by cholera toxin. 
We suggest hat this activity might reflect the func- 
tioning of the putative Gins [5,20-241. 
2. MATERIALS AND METHODS 
Cholera toxin, insulin (porcine), adrenaline and 
propranolol were from Sigma (Poole, England). 
Vasopressin was from BRL (Paisley, Scotland). 
Purified pertussis toxin was from Professor J. 
Freer (Department of Microbiology, University of 
Glasgow, Scotland). All other biochemicals were 
from Boehringer (Lewes, England). [y-32P]GTP 
was from Amersham International (Amersham, 
England). All other chemicals were of AR grade 
from BDH (Poole, England). 
Blood was obtained from the antecubital vein of 
normal healthy volunteers who were not undergo- 
ing medication and had not undergone medication 
for at least 1 month before the experiments. 
Platelets were prepared as described in [27] and 
membranes according to [28]. 
GTPase activity was measured as described 
before by us [16] monitoring the liberation of 32P 
from [Y-~~P]GTP, essentially as in [29]. The assay, 
in a final volume of 100 yl, contained 0.4/1M 
[y-32P]GTP, 5 mM MgC12, 100 mM NaCl, 1 mM 
dithiothreitol, 0.5 mM EGTA, 1 mM adenylyl im- 
idodiphosphate (AMP-PNP), 50 mM Tris-HCl 
buffer (pH 7.4) and the appropriate drugs. The 
high-affinity component was identified [29] by car- 
rying out the assays in the presence and absence of 
added unlabelled GTP (1OOpM). Linear time 
courses, at 3O”C, were obtained in all instances 
over a 10 min period, during which initial rates 
were assessed. 
Platelet membranes were treated with either 
cholera toxin or pertussis toxin that had been thiol 
pre-activated by using a modification of the 
method described in [31] and discussed by us 
previously in some detail [24]. Briefly, platelet 
membranes were incubated in ‘ribosylation’ mix- 
ture containing 1 mM NAD+, 0.5 mM GTP, 
15 mM thymidine, and 100 mM potassium 
phosphate buffer, final pH 7.5. For treatment with 
cholera toxin, the incubation was performed for 
10 min at 30°C with 1OOpg toxin/ml, and with 
pertussis toxin for 30 min at 37°C with 50 pg tox- 
in/ml. In each case, appropriate control incuba- 
tions were done in the absence of toxin. After the 
incubation the membranes were pelleted by cen- 
trifugation at 12000 x g for 15 min at 4°C and 
washed twice by centrifugation with resuspension 
in the GTPase assay mixture. Membranes were 
kept on ice before their use. 
3. RESULTS AND DISCUSSION 
It has been well established that human platelets 
contain functional G, and Gi, with appropriate 
receptors able to elicit the stimulation of high- 
affinity GTPase activity [1,12,13,30]. As shown 
here (table 1) and as has been reported previously 
by us [14,16], PGEi will stimulate the GTPase ac- 
tivity of G,; adrenaline, when added together with 
propranolol in order to block &adrenoreceptor 
responses, will stimulate the GTPase activity of Gi 
through binding to the a2-adrenoceptor and the ac- 
tivity of the putative Gp, a G-protein suggested [17] 
to be involved in mediating the actions of hor- 
mones which stimulate inositol phospholipid 
metabolism was stimulated by vasopressin (table 
1). We make here, however, the novel observation 
that insulin can stimulate a high-affinity GTPase 
activity in human platelets (table 1) which ex- 
hibited a K,,, of 0.6 yM for GTP. This compares 
with Km values of 0.3 and 0.5 PM GTP that we 
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Fig. I. Insulin-stimulated high-affinity GTPase activity 
in human platelet membranes. Insulin-stimulated 
GTPase activity of human platelet membranes in a dose- 
dependent fashion. High-affinity GTPase activity was 
determined as described in section 2 in the presence of 
0.7pM GTP. Data presented are the average of three 
separate experiments using different platelet membrane 
preparations with errors given as + SE with n = 3. 
observed in this study for the GTPase activities 
stimulated by G, (PGEi-stimulated) and Gi 
(adrenaline + propranolol), respectively. Such 
values are close to those reported by others in 
platelets [12,18] and other tissues [13,32,33] for the 
GTPase activities of G, and Gi. 
Insulin stimulated platelet membrane GTPase 
activity in a dose-dependent fashion, exhibiting a 
Ka of 3.1 1+ 1 .O nM insulin (fig.1; errors are SE, 
n = 3). This is close to the values of -3-6 nM for 
half-maximal saturation/displacement reported 
for the specific binding of insulin to receptors on 
human platelets [2,3]. The maximal stimulation of 
GTPase activity elicited by insulin was 62 k 5% 
over that of control activity, which is of the order 
of that seen for ligands which stimulated the activi- 
ty of other G-protein GTPases in platelets (table 
1). 
Treatment of isolated platelet membranes with 
either activated pertussis or cholera toxin had little 
effect on the vasopressin-stimulated GTPase ac- 
tivity (table 1) as noted before by us [14,16]. This 
is in accord with observations made both by us [14] 
and others [15] that the putative G, in platelets is 
not affected by treatment with either of these tox- 
ins. Pertussis toxin causes the inactivation of Gi 
[7,8] and we noted in these studies that treatment 
of platelet membranes with activated pertussis tox- 
in did cause the inactivation of Gi (table 1; 
Table 1 
Selective inhibition of GTPase activity elicited by the treatment of platelet membranes 
with pertussis and cholera toxins 
96 
Stimulatory Putative Increase in basal GTPase activity (070) 
ligand G-protein 
modified Stimulation in After treatment After treatment 
absence of with cholera with pertussis 
toxin treatment toxin toxin 
PGE, G, 113 f 8 26 k 10 101 + 12 
Adrenaline + 
propranolol Gi 128k 7 113 + 12 64 + 11 
Vasopressin G, 34* 7 28+ 5 31k 6 
Insulin Gins 60+ 3 6k 4 59k 5 
Platelet membranes were incubated with thiol pre-activated toxins as detailed in section 
2. Ligand-stimulated high-affinity GTP activity was assessed in the presence of PGEI 
(20 FM), adrenaline (100 pM) + propranolol (1 PM), vasopressin (10 nM) and insulin 
(100 nM). Data are given f SD for n = 3 separate xperiments. Activities are given as the 
percentage increase in the observed basal activity caused by ligand addition. Basal GTPase 
activity was 47 pmol/min per mg protein 
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[ 14- 161) as indicated by the reduction in GTPase 
stimulation elicited by adrenaline (+ propranolol). 
However, the action of pertussis toxin had no ef- 
fect on the insulin-stimulated GTPase activity of 
platelet membranes (table 1). In contrast, treat- 
ment of platelet membranes with activated cholera 
toxin inhibited not only the functioning of G,, as 
indicated by the reduced PGEi-stimulated GTPase 
activity, but also the GTPase activity stimulated by 
insulin (table 1). We consider it highly unlikely, 
however, that insulin exerts actions by stimulating 
G,. Evidence that insulin does not stimulate G, 
comes from two observations. Firstly, in no in- 
stance has insulin been shown to stimulate the ac- 
tivity of adenylate cyclase, rather it has been 
shown to inhibit this enzyme and to decrease in- 
tracellular cyclic AMP concentrations in various 
tissues (see [5,20-221). Secondly, we observed here 
that cholera toxin appeared to be somewhat more 
effective at inhibiting the insulin-stimulated 
GTPase (91070) than that of G, (77%) (table 1). 
Thirdly, mixed ligand experiments (table 2) also in- 
dicated that insulin stimulated a distinct GTPase. 
These experiments were performed by adding 
stimulatory ligands both individually and as pairs 
in combination. A mixed ligand ratio was then ex- 
pressed as the ratio of the GTPase stimulation 
observed in the presence of a pair of ligands added 
together to the assay, divided by the sum of the in- 
dividual stimulations seen when the ligands were 
added to separate assays. It follows that for 
ligands which stimulate distinct GTPases, then full 
additivity of stimulation will ensue and this ratio 
will be equal to unity. In contrast, for ligands 
which stimulate a common GTPase then stimula- 
tion will not be additive and this ratio will be equal 
to 0.5 under conditions where the individual 
ligands are capable of maximally stimulating one 
particular G-protein (GTPase). This is readily 
demonstrated for a combination of PGEi and 
isoprenaline (&adrenoceptor) which both 
stimulate G, and here yielded a mixed ligand ratio 
of near 0.5 (table 2). In contrast, for ligands which 
stimulated two distinct G-proteins, such as can be 
seen using the combination of PGEl and 
adrenaline (+ propranolol), which stimulated G, 
and Gi respectively, a ‘mixed ligand’ ratio of 1.0 
was obtained (table 2). We see, however, that when 
insulin was studied in combination with PGEi, a 
mixed ligand ratio of 1.0 ensued (table 2). This 
supports the notion that insulin does not act to 
stimulate the GTPase activity of G,. Indeed, a 
similar ratio of near unity was obtained when in- 
sulin was added together with adrenaline 
(+ propranolol) and also with vasopressin, thus 
demonstrating that insulin did not stimulate the 
GTPase activity of either Gi or the putative G,. 
That the GTPase activity stimulated by insulin 
was inactivated by treatment with cholera toxin is 
in accord with our earlier observations concerning 
Table 2 
Mixed ligand experiments on human platelet high- 
affinity GTPase activity 
Ligand mixture G-proteins Mixed ligand 
involved ratio 
PGE, 









1.1 f 0.10 
GS 
GP 
0.98 f 0.08 
GS 
GS 
0.58 f 0.06 
GS 
Gins 









+ adrenaline (propranolol) 
Gi 
Gi, 
1.1 -t 0.11 
G, 
Gi 
0.9 + 0.09 
High-affinity GTPase activity was determined in platelet 
plasma membranes using 0.7,~M GTP, as described in 
section 2. The percentage stimulation of this GTPase 
activity,over the control activity (100%) was determined 
in the presence of various ligands added either alone or 
in pairs. Maximally effective concentrations of ligands 
were used, 100 nM insulin, 10 nM vasopressin, 1OOpM 
isoprenaline, 20 PM PGEt and 100 PM adrenaline (plus 
1 yM propranolol). The mixed ligand ratio was 
expressed as the percentage stimulation observed by 
adding the appropriate pair of ligands together to the 
GTPase assay, divided by the sum of the stimulation of 
GTPase activity observed when each ligand was added 
separately. For ligands acting to stimulate a single 
GTPase, this ratio will be equal to 0.5, whereas for those 
which stimulate distinct GTPase this ratio will be equal 
to 1.0. Errors are given as SD for n = 3 experiments 
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the ability of insulin to elicit the inhibition of 
adenylate cyclase [22] and activation of a 
peripheral plasma membrane cyclic AMP 
phosphodiesterase 1231. These indicated that the 
putative Gins could be functionally activated by 
cholera toxin. 
We would like then to suggest that insulin 
stimulates the GTPase activity of a novel G- 
protein in human platelets. This activity may 
reflect the functioning of the putative Gins (20-221. 
It has been demonstrated that purified, solubilised 
insulin receptor can phosphorylate the G-proteins 
Gi, G, [34] and transducin [35]. However, ex- 
periments conducted here show that insulin can 
stimulate a specific platelet GTPase activity in the 
absence of ATP. This suggests that the insulin 
receptor might interact directly with the G-protein, 
although we cannot rule out the possibility that the 
membrane-bound receptor could utilise GTP as a 
phosphate donor. 
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